ABI Genetic Analyzer-DNA Sequencer 3100

ABI基因分析仪-DNA测序仪3100

• 批准号: 6440380
• 负责人: JOHN C HUTTON
• 金额: $ 13.65万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6440380
• 关键词: biomedical equipment purchase; computer assisted sequence analysis; high throughput technology; nucleic acid sequence

The current proposal is from a group of principal investigators at the University of Colorado Health Sciences Center who have a pressing need for high throughput and automated sequencing and genotyping as a primary research tool. The goal of this proposal is to generate funds to purchase a new Applied Biosystems Genetic Analyzer-DNA Sequencer 3100 to accommodate the increasing demands of the expanding user group at the University of Colorado Health Sciences Center campus. The dominant user group is comprised of faculty members in the existing Diabetes and Endocrinology Research Center (DERC) at the University of Colorado School of Medicine. The user group includes 8 principal investigators at the Barbara Davis Center for Childhood Diabetes, including its Executive Director (G. Eisenbarth) and Research Director (J. Hutton) and additional UCHSC investigators who are DERC members, including the Head of Clinical Immunology (B. Kotzin). At the time of this application, the major users are recipients of over 4 million dollars in yearly NIH support. The instrument requested will alleviate the chronic backlog of sequencing services presently provided to the user group by a single capillary ABI 310 sequencer purchased in 1998 and operated by the newly established DERC molecular core. The instrument requested will be operated and managed using the DERC core facility at the Barbara Davis Center for Childhood Diabetes and its acquisition will permit the user group to more efficiently perform high throughput DNA sequencing. The current instrumentation processes one sample at a time whereas the requested equipment will allow the simultaneous processing of 36 samples per hour. User fees will be charged to fund the management and maintenance of the instrument. Although projected usage should provide enough funding, operating costs not covered by these fees will be absorbed by the Barbara Davis Center with funds provided by the DERC. An advisory group comprised of the DERC molecular core directors (L.Sussel and J. Hutton), two user representatives (one BDC and one non-BDC), and the core manager (S. Hawkes) will provide a balanced management policy for all users.

目前的提议来自科罗拉多大学健康科学中心的一组主要研究人员，他们迫切需要高通量和自动测序和基因分型作为主要研究工具。该提案的目标是筹集资金购买新的应用生物系统遗传分析仪-DNA测序仪3100，以满足科罗拉多大学健康科学中心校园不断扩大的用户群日益增长的需求。主要用户群由科罗拉多大学医学院现有糖尿病和内分泌学研究中心（DERC）的教员组成。用户组包括芭芭拉戴维斯儿童糖尿病中心的8名主要研究人员，包括其执行主任（G。Eisenbarth）和研究总监（J.赫顿）以及DERC成员的其他UCHSC研究者，包括临床免疫学负责人（B. Kotzin）。在提出这一申请时，主要用户是每年获得国家卫生研究院400多万美元支持的人。所要求的仪器将减轻目前由1998年购买的单一毛细管ABI 310测序仪向用户群提供的测序服务的长期积压，该测序仪由新成立的DERC分子核心操作。所要求的仪器将使用芭芭拉戴维斯儿童糖尿病中心的DERC核心设施进行操作和管理，其收购将允许用户组更有效地进行高通量DNA测序。目前的仪器每次处理一个样品，而要求的设备将允许每小时同时处理36个样品。将收取使用费，以资助仪器的管理和维护。虽然预计的使用应该提供足够的资金，运营成本不包括这些费用将吸收芭芭拉戴维斯中心与资金提供的DERC。一个由DERC分子核心主任（L.Sussel和J.赫顿）、两名用户代表（一名BDC和一名非BDC）和核心经理（S. Hawkes）将为所有用户提供平衡的管理策略。